Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | PPM1B | O75688 | 1/20 | 0.33 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.33 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.33 |
| ▸ | PPP5C | P53041 | 1/20 | 0.33 |
| ▸ | PPP2CA | P67775 | 1/20 | 0.33 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GMNN | O75496 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5305197 | 1.00 | TP53 (0.33) | TP53CYP3A4MAPK1LMNAHIF1A | |
| SCHEMBL7262112 | 0.80 | — | — | |
| SCHEMBL14566659 | 0.80 | — | — | |
| SCHEMBL5301166 | 0.80 | — | — | |
| SCHEMBL4653435 | 0.80 | — | — | |
| SCHEMBL13204860 | 0.77 | TP53 (0.32) | TP53CYP3A4MAPK1LMNAHIF1A | |
| SCHEMBL13204871 | 0.77 | TP53 (0.32) | TP53CYP3A4MAPK1LMNAHIF1A | |
| SCHEMBL475787 | 0.77 | TP53 (0.32) | TP53CYP3A4MAPK1LMNAHIF1A | |
| SCHEMBL13222520 | 0.77 | TP53 (0.32) | TP53CYP3A4MAPK1LMNAHIF1A | |
| SCHEMBL8846091 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344132-B2 | Methods for the preparation of 9-deazapurine derivatives | BioCryst Pharmaceticals, Inc. (US) | 2013-01-01 | — | — | US | claimed |
| US-20100093991-A1 | METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES | BIO CRYST PHARMACEUTICALS , INC. (US) | 2010-04-15 | — | — | US | claimed |
| US-7598373-B2 | Process for the production of 2-C-methyl-D-ribonolactone | IDENIX PHARMACEUTICALS, INC. (US) | 2009-10-06 | — | — | US | claimed |
| EP-1585529-A4 | PROCESS FOR THE PRODUCTION OF 2'-BRANCHED NUCLEOSIDES | IDENIX CAYMAN LTD (KY) | 2008-05-28 | — | — | EP | claimed |
| EP-1893625-A2 | METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES | Biocryst Pharmaceuticals, Inc. (US) | 2008-03-05 | — | — | EP | claimed |
| WO-2007002191-A2 | METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2007-01-04 | — | — | WO | claimed |
| EP-1585529-A2 | PROCESS FOR THE PRODUCTION OF 2'-BRANCHED NUCLEOSIDES | Idenix (Cayman) Limited (KY) | 2005-10-19 | — | — | EP | claimed |
| US-20050020825-A1 | Process for the production of 2'-branched nucleosides | IDENIX PHARMACEUTICALS LLC | 2005-01-27 | — | — | US | claimed |
| WO-2004052899-A2 | PROCESS FOR THE PRODUCTION OF 2'-BRANCHED NUCLEOSIDES | IDENIX (CAYMAN) LIMITED (KY) | 2004-06-24 | — | — | WO | claimed |
| US-20150126752-A1 | PROCESS FOR THE PREPARATION OF 2-C-METHYL-D-RIBONIC-GAMMA-LACTONE | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-07 | — | — | US | disclosed |
| EP-2864303-A1 | PROCESS FOR THE PREPARATION OF 2-C-METHYL-D-RIBONIC-GAMMA-LACTONE | Bristol-Myers Squibb Company (US) | 2015-04-29 | — | — | EP | disclosed |
| CN-104520281-A | Process for the preparation of 2-C-methyl-D-ribonic-gamma-lactone | BRISTOL MYERS SQUIBB CO | 2015-04-15 | — | — | CN | disclosed |
| EP-2319853-B1 | Process for the production of 2'-branched nucleosides | IDENIX PHARMACEUTICALS INC (US) | 2014-03-12 | — | — | EP | disclosed |
| WO-2013188480-A1 | PROCESS FOR THE PREPARATION OF 2-C-METHYL-D-RIBONIC-GAMMA-LACTONE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-12-19 | — | — | WO | disclosed |
| US-6143443-A | ALL-VANADIUM REDOX BATTERY, COMPRISING THE STABILIZED ELECTROLYTE | PINNACLE ARB LIMITED (AU) | 2000-11-07 | — | — | US | disclosed |
| EP-0829104-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1998-03-18 | — | — | EP | disclosed |
| EP-0729648-A4 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LTD (AU) | 1997-01-02 | — | — | EP | disclosed |
| WO-1996035239-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-11-07 | — | — | WO | disclosed |
| EP-0729648-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-09-04 | — | — | EP | disclosed |
| WO-1995012219-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1995-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093991-A1 | METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES | DPYD, TYMP, UNG | TP53 1565/4885CYP3A4 705/4885MAPK1 4022/4885 |
| US-20150126752-A1 | PROCESS FOR THE PREPARATION OF 2-C-METHYL-D-RIBONIC-GAMMA-LACTONE | RNGTT, FBL, NSUN2 | TP53 3910/4885CYP3A4 3115/4885MAPK1 1055/4885 |
| US-20050020825-A1 | Process for the production of 2'-branched nucleosides | RNGTT, MTAP, NSUN2 | TP53 4226/4885CYP3A4 709/4885MAPK1 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.